Janssen Collaborates with Vor to Develop Engineered Hematopoietic Stem Cell Transplants with Bi-Specific Antibody Therapy to Treat AML

July 9, 2021 Auto Bot Biotech 0

Shots:

  • The collaboration will evaluate the combination of Vor’s eHSC transplant platform with Janssen’s bi-specific Abs for the treatment of AML
  • The agreement stated that each company retains all rights and ownership to their respective programs and platforms
  • The combination will utilize each technology’s strengths for protecting patients against off-target effects of immunotherapies

Click here to read full press release/ article | Ref: Globe Newswire | Image: Biotech Finances

The post Janssen Collaborates with Vor to Develop Engineered Hematopoietic Stem Cell Transplants with Bi-Specific Antibody Therapy to Treat AML first appeared on PharmaShots.